

David C Cipolla

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5159244/publications.pdf>

Version: 2024-02-01

64
papers

2,241
citations

218677

26
h-index

223800

46
g-index

65
all docs

65
docs citations

65
times ranked

2262
citing authors

#	ARTICLE	IF	CITATIONS
1	Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial. <i>Thorax</i> , 2013, 68, 812-817.	5.6	221
2	Production of solid lipid nanoparticle suspensions using supercritical fluid extraction of emulsions (SFEE) for pulmonary delivery using the AERx system. <i>Advanced Drug Delivery Reviews</i> , 2007, 59, 444-453.	13.7	190
3	Development of Liposomal Ciprofloxacin to Treat Lung Infections. <i>Pharmaceutics</i> , 2016, 8, 6.	4.5	146
4	Liposomal formulations for inhalation. <i>Therapeutic Delivery</i> , 2013, 4, 1047-1072.	2.2	120
5	Lipid-based carriers for pulmonary products: Preclinical development and case studies in humans. <i>Advanced Drug Delivery Reviews</i> , 2014, 75, 53-80.	13.7	107
6	Drug nanocrystallisation within liposomes. <i>Journal of Controlled Release</i> , 2018, 288, 96-110.	9.9	100
7	Pulmonary Formulations: What Remains to be Done?. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2010, 23, S-5-S-23.	1.4	91
8	Physical stability of dry powder inhaler formulations. <i>Expert Opinion on Drug Delivery</i> , 2020, 17, 77-96.	5.0	89
9	Liposomal Nanoparticles Control the Uptake of Ciprofloxacin Across Respiratory Epithelia. <i>Pharmaceutical Research</i> , 2012, 29, 3335-3346.	3.5	75
10	Minimizing Variability of Cascade Impaction Measurements in Inhalers and Nebulizers. <i>AAPS PharmSciTech</i> , 2008, 9, 404-413.	3.3	54
11	Equivalence Considerations for Orally Inhaled Products for Local Action. ISAM/IPAC-RS European Workshop Report. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2012, 25, 117-139.	1.4	54
12	Aerosolized Protein Delivery in Asthma: Gamma Camera Analysis of Regional Deposition and Perfusion. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2001, 14, 185-195.	1.2	53
13	Development and Characterization of an In Vitro Release Assay for Liposomal Ciprofloxacin for Inhalation. <i>Journal of Pharmaceutical Sciences</i> , 2014, 103, 314-327.	3.3	49
14	Modifying the Release Properties of Liposomes Toward Personalized Medicine. <i>Journal of Pharmaceutical Sciences</i> , 2014, 103, 1851-1862.	3.3	49
15	Ciprofloxacin nanocrystals liposomal powders for controlled drug release via inhalation. <i>International Journal of Pharmaceutics</i> , 2019, 566, 641-651.	5.2	47
16	In vitro and ex vivo methods predict the enhanced lung residence time of liposomal ciprofloxacin formulations for nebulisation. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2014, 86, 83-89.	4.3	46
17	Inhaled antibiotics to treat lung infection. <i>Pharmaceutical Patent Analyst</i> , 2013, 2, 647-663.	1.1	44
18	Inhaled Medicines: Past, Present, and Future. <i>Pharmacological Reviews</i> , 2022, 74, 48-118.	16.0	44

#	ARTICLE	IF	CITATIONS
19	Formulation technology to repurpose drugs for inhalation delivery. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2011, 8, 123-130.	0.5	41
20	Recent advances in prodrug-based nanoparticle therapeutics. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2021, 165, 219-243.	4.3	41
21	Formation of drug nanocrystals under nanoconfinement afforded by liposomes. <i>RSC Advances</i> , 2016, 6, 6223-6233.	3.6	38
22	Characterization of aerosols of human recombinant deoxyribonuclease I (rhDNase) generated by jet nebulizers. <i>Pharmaceutical Research</i> , 1994, 11, 491-498.	3.5	35
23	Modeling of a spray drying method to produce ciprofloxacin nanocrystals inside the liposomes utilizing a response surface methodology: Box-Behnken experimental design. <i>International Journal of Pharmaceutics</i> , 2021, 597, 120277.	5.2	31
24	Personalizing aerosol medicine: development of delivery systems tailored to the individual. <i>Therapeutic Delivery</i> , 2010, 1, 667-682.	2.2	30
25	Changes in respiratory symptoms during 48-week treatment with ARD-3150 (inhaled liposomal) Tj ETQq1 1 0.784314 rgBT /Overlock 10 <i>Journal</i> , 2020, 56, 2000110.	6.7	30
26	Urgent Appeal from International Society for Aerosols in Medicine (ISAM) During COVID-19: Clinical Decision Makers and Governmental Agencies Should Consider the Inhaled Route of Administration: A Statement from the ISAM Regulatory and Standardization Issues Networking Group. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2020, 33, 235-238.	1.4	27
27	Investigation of protein-surfactant interactions by analytical ultracentrifugation and electron paramagnetic resonance: the use of recombinant human tissue factor as an example. <i>Pharmaceutical Research</i> , 1999, 16, 808-812.	3.5	26
28	Effective Treatment of Mycobacterium avium subsp. hominissuis and Mycobacterium abscessus Species Infections in Macrophages, Biofilm, and Mice by Using Liposomal Ciprofloxacin. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	25
29	Aerosol Performance and Stability of Liposomes Containing Ciprofloxacin Nanocrystals. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2015, 28, 411-422.	1.4	23
30	Patient Focus and Regulatory Considerations for Inhalation Device Design: Report from the 2015 IPAC-RS/ISAM Workshop. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2017, 30, 1-13.	1.4	23
31	Robustness of aerosol delivery of amikacin liposome inhalation suspension using the eFlow [®] Technology. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2021, 166, 10-18.	4.3	23
32	Will pulmonary drug delivery for systemic application ever fulfill its rich promise?. <i>Expert Opinion on Drug Delivery</i> , 2016, 13, 1337-1340.	5.0	22
33	Tuning Ciprofloxacin Release Profiles from Liposomally Encapsulated Nanocrystalline Drug. <i>Pharmaceutical Research</i> , 2016, 33, 2748-2762.	3.5	20
34	Direct Comparison of Standard Transmission Electron Microscopy and Cryogenic-TEM in Imaging Nanocrystals Inside Liposomes. <i>Molecular Pharmaceutics</i> , 2019, 16, 1775-1781.	4.6	18
35	Formation of ciprofloxacin nanocrystals within liposomes by spray drying for controlled release via inhalation. <i>International Journal of Pharmaceutics</i> , 2020, 578, 119045.	5.2	18
36	Aerosol Performance and Long-Term Stability of Surfactant-Associated Liposomal Ciprofloxacin Formulations with Modified Encapsulation and Release Properties. <i>AAPS PharmSciTech</i> , 2014, 15, 1218-1227.	3.3	17

#	ARTICLE	IF	CITATIONS
37	Inhaled nicotine replacement therapy. <i>Asian Journal of Pharmaceutical Sciences</i> , 2015, 10, 472-480.	9.1	15
38	Controlling the size and shape of liposomal ciprofloxacin nanocrystals by varying the lipid bilayer composition and drug to lipid ratio. <i>Journal of Colloid and Interface Science</i> , 2019, 555, 361-372.	9.4	13
39	Storage stability of inhalable, controlled-release powder formulations of ciprofloxacin nanocrystal-containing liposomes. <i>International Journal of Pharmaceutics</i> , 2021, 605, 120809.	5.2	13
40	Solid State Characterization of Ciprofloxacin Liposome Nanocrystals. <i>Molecular Pharmaceutics</i> , 2019, 16, 184-194.	4.6	12
41	Nanoscale Probing of Liposome Encapsulating Drug Nanocrystal Using Atomic Force Microscopy-Infrared Spectroscopy. <i>Analytical Chemistry</i> , 2020, 92, 9922-9931.	6.5	12
42	Strategies to Overcome Biological Barriers Associated with Pulmonary Drug Delivery. <i>Pharmaceutics</i> , 2022, 14, 302.	4.5	12
43	Sweetening Inhaled Antibiotic Treatment for Eradication of Chronic Respiratory Biofilm Infection. <i>Pharmaceutical Research</i> , 2018, 35, 50.	3.5	11
44	Microbiological changes observed over 48 weeks of treatment with inhaled liposomal ciprofloxacin in individuals with non-cystic fibrosis bronchiectasis and chronic <i>Pseudomonas aeruginosa</i> lung infection. <i>Clinical Microbiology and Infection</i> , 2019, 25, 1532-1538.	6.0	11
45	Prostanoid receptor subtypes involved in treprostinil-mediated vasodilation of rat pulmonary arteries and in treprostinil-mediated inhibition of collagen gene expression of human lung fibroblasts. <i>Prostaglandins and Other Lipid Mediators</i> , 2021, 152, 106486.	1.9	11
46	Development and Characterization of Treprostinil Palmitil Inhalation Aerosol for the Investigational Treatment of Pulmonary Arterial Hypertension. <i>International Journal of Molecular Sciences</i> , 2021, 22, 548.	4.1	9
47	Characterisation of cough evoked by inhaled treprostinil and treprostinil palmitil. <i>ERJ Open Research</i> , 2021, 7, 00592-2020.	2.6	8
48	Current and Emerging Inhaled Therapies of Repositioned Drugs. <i>Advanced Drug Delivery Reviews</i> , 2018, 133, 1-4.	13.7	7
49	Reflections on Digital Health Tools for Respiratory Applications. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2020, 33, 127-132.	1.4	7
50	Safety, Tolerability And Pharmacokinetics Of Novel Liposomal Ciprofloxacin Formulations For Inhalation In Healthy Volunteers And Non-Cystic Bronchiectasis Patients. , 2010, , .		5
51	Comment on: Inhaled antimicrobial therapy—Barriers to effective treatment, by J. Weers, <i>Inhaled antimicrobial therapy — Barriers to effective treatment</i> , <i>Adv. Drug Deliv. Rev.</i> (2015), http://dx.doi.org/10.1016/j.addr.2014.08.013 . <i>Advanced Drug Delivery Reviews</i> , 2015, 85, e6-e7.	13.7	5
52	Development and Preclinical Evaluation of New Inhaled Lipoglycopeptides for the Treatment of Persistent Pulmonary Methicillin-Resistant <i>Staphylococcus aureus</i> Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0031621.	3.2	5
53	Treprostinil palmitil, an inhaled long-acting pulmonary vasodilator, does not show tachyphylaxis with daily dosing in rats. <i>Pulmonary Pharmacology and Therapeutics</i> , 2021, 66, 101983.	2.6	4
54	Treprostinil palmitil inhibits the hemodynamic and histopathological changes in the pulmonary vasculature and heart in an animal model of pulmonary arterial hypertension. <i>European Journal of Pharmacology</i> , 2022, 916, 174484.	3.5	4

#	ARTICLE	IF	CITATIONS
55	AERx® Pulmonary Drug Delivery Systems. , 2008, , 563-571.		3
56	Open-label extension (OLE) of ORBIT-3 and ORBIT-4 trials of ARD-3150 in non-cystic fibrosis bronchiectasis (NCFB). , 2018, , .		2
57	Reduction of pulmonary exacerbations in two phase 3 Trials: in-depth analyses. , 2018, , .		1
58	Effect of prior year pulmonary exacerbation (PE) frequency on response to ARD-3150 in patients with non-cystic fibrosis bronchiectasis (NCFB) chronically infected with Pseudomonas aeruginosa (PA). , 2018, , .		1
59	Changes in respiratory symptoms during 48 weeks treatment with ARD-3150 (inhaled liposomal) Tj ETQq1 1 0.784314 rgBT 1/Overlock		1
60	Late Breaking Abstract - Reduction in frequency of pulmonary exacerbations (PE) with inhaled ARD-3150 in non-cystic fibrosis bronchiectasis (NCFB) patients is independent of Pseudomonas aeruginosa (PA) susceptibility at baseline. , 2017, , .		1
61	Robustness of assessment of pulmonary endpoints in phase 3 trials with ARD-3150 in non-cystic fibrosis bronchiectasis (NCFB) patients with chronic Pseudomonas aeruginosa (PA) infections. , 2018, , .		1
62	Comparison of Treprostinil Palmitil Inhalation Suspension (TPIS) or Oral Sildenafil (Sild) in a Sugden/Hypoxia Rat Model of PAH. , 2020, , .		0
63	Hemodynamic and histological progression in the Sugden-Hypoxia Rat Model. , 2020, , .		0
64	No evidence of desensitization to repeat dosing with treprostinil palmitil inhalation suspension (TPIS) for 32-consecutive days in hypoxia-challenged telemetered rats. , 2020, , .		0